| Jul 28 |
Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
|
| Jul 25 |
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
|
| Jul 16 |
Viridian, Pharvaris said to be among prime M&A targets for Biogen
|
| Jun 12 |
Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
|
| Jun 11 |
Viridian gains after R&D update; Wolfe starts at Outperform
|
| Jun 11 |
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
|
| May 31 |
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
|
